• NaomiPearce

Tysabri® | Natalizumab | Biogen/Elan

10 Sep 2020 | All | All | Neurology Advisor reports a new study indicates that natalizumab may be more effective than fingolimod or BRACETD in reducing relapses in patients with relapsing-remitting multiple sclerosis.

21 Nov 2019 | All | Polpharma/Sandoz | Polpharma commences dosing in Phase III trials of proposed natalizumab biosimilar.

12 Oct 2019 | All | Polpharma/Sandoz | Polpharma publishes details of upcoming phase III clinical trials of biosimilar natalizumab candidate. The study will involve approximately 260 patients with relapsing-remitting multiple sclerosis.

03 Sep 2019 | All | Pfizer & Polpharma Biologics | Pfizer and Polpharma announce licensing deal for natalizumab biosimilar. Under the agreement, Polpharma will develop, manufacture and supply the product, while Sandoz will be responsible for commercialisation and distribution.

Biosimilars Bulletin 
Search by tags

© 2019 Pearce IP | Australia

  • LinkedIn Social Icon